Nucala (mepolizumab) for the Treatment of Hypereosinophilic Syndrome (HES)

Image 2-Nucala (mepolizumab)
Mepolizumab is an IL-5-inhibiting humanised monoclonal antibody. Credit: GlaxoSmithKline.